secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verastem, Inc. (VSTM)
CIK:        0001526119
Form:       8-K
Filed at:   2026-06-17T12:52:16+00:00
Accession:  0001104659-26-074915
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verastem reports 86% 6-month OS rate in RAMP 205 pancreatic cancer trial; starts VS-7375 Phase 2
--------------------------------------------------------------------------------

- 6-month OS rate 86%, ORR 52%, and 83% tumor shrinkage in RAMP 205 RP2D cohort (n=29).
- 9 patients remain on treatment; median follow-up 9.8 months; no new safety signals.
- First patient dosed in TARGET-D 201 Phase 2 registration trial of VS-7375 (KRAS G12D) in second-line mPDAC.
- PanCAN provided $3.8M Therapeutic Accelerator Award in 2022 for RAMP 205 research.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1526119/000110465926074915/0001104659-26-074915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1526119/000110465926074915/tm2618108d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-074915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer